Assistant Senior Biochemist at Eli Lilly & Co. to Present at GTCbio’s 2nd Rediscovering Biomarkers conference on July 10-11

Jon Butler, Assistant Senior Biochemist at Eli Lilly & Co. to Present at GTCbio’s 2nd Rediscovering Biomarkers conference on July 10-11, 2008 in Boston, MA

April 24, 2008 (FPRC) -- Dr. Jon Butler, Assistant Senior Biochemist at Eli Lilly & Co. will be presenting at GTCbio’s 2nd Annual Rediscovering Biomarkers conference on July 10-11, 2008 in Boston, MA. Dr. Butler will speak on “Utilizing a LC/MS/MS/MRM Quantitative Targeted Biomarker Panel to Elucidate Multiple Biological Changes Simultaneously.”
Biomarkers are commonly used to characterize a disease and/or follow disease state progression. Biological processes can be complex and have multiple feedback mechanisms to keep them in a regulated state. When these systems begin to fail, a single biomarker may not reflect that the process is in an uncontrolled state. Biomarker panels can be a tool used to help elucidate these complex biological systems, one such system is that of musculoskeletal diseases. A protein biomarker panel can show processes involved in disease and/or disease states thus allowing the striation of patients for tailored therapeutics. Musculoskeletal diseases in humans result in extended medical costs but more importantly reduce the quality of patient life. Muscle physiology has been characterized at the message level and here we extend that to the protein level via tissue extracts from mouse atrophy models as compared to controls. Global proteome profiling is used along with in-silico protein digestion followed by MRM development to create a panel of proteins involved in muscle physiology. These processes narrow down proteins amendable to detection with this technology. LC/MS/MS/MRM is used to quantitate changes due to perturbations in these animal models. This panel can be used to access early changes in muscle physiology which currently is measured at a much later time point by size and/or strength.
The 2nd Annual Rediscovering Biomarkers Conference will expose attendees to the latest advancements and developments in biomarkers and predictive medicine. Attendees will gain insight into discovery and development processes, hear about new biomarkers and upcoming trends in the industry, as well as the status of those in clinical trials. Delegates will also receive highly valuable information on tools for improving reimbursement strategies and the efficacy and validation of biomarkers.

For more information including a detailed agenda, exhibitor opportunities and registration information visit http://gtcbio.com/conferenceDetails.aspx?id=124
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com


For more information contact Rania Hafez of GTCbio (http://www.gtcbio.com)
(626) 256-6405

Keywords: biomarkers

You can read this press release online at: http://www.free-press-release-center.info/pr00000000000000013998.html